Drug Trial Radar · NCT07619898
PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure
Last checked: Nov 20, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
112
Planned (sponsor's estimate)
Start
Jul 2026
Primary completion
Dec 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- Therakos LLCIndustry
- Sponsor type
- Industry
- First posted
- Jun 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Extracorporeal photopheresis (ECP) is an immunomodulatory therapy in which the photoactivating agent methoxsalen (also known as UVADEX) is used in combination with ultraviolet A (UVA) light. Immune checkpoint inhibitor therapy is widely used for the treatment of several cancers, including melanoma. However, a common immune-related adverse event associated with this therapy is Immune-related colitis or hepatitis. Corticosteroids are typically the first-line treatment for this condition, but some participants do not respond adequately. The purpose of this study is to evaluate the efficacy of ECP in the treatment of immune-related (ir)-colitis and ir-hepatitis with inadequate response to corticosteroids, and to compare its efficacy to other second-line immunosuppressant therapies. The ECP procedure in this study is performed using the CELLEX® device, a fully closed-loop extracorporeal blood circulation device. The CELLEX device is used in conjunction with methoxsalen.
Conditions
- Colitis
- Hepatitis
- Melanoma (Skin Cancer)
Interventions
methoxsalenDrug
Sterile solution used in conjunction with CELLEX ECP
Extracorporeal photopheresis (ECP)Device
Methoxsalen is used in conjunction with the CELLEX ECP
VedolizumabDrug
Vedolizumab will be administered intravenously
InfliximabDrug
Infliximab will be administered intravenously
Mycophenolate Mofetil (MMF)Drug
Mycophenolate Mofetil will be administered orally or intravenously
AzathioprineDrug
Azathioprine will be administered orally or intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants Who are in Steroid-free response at Week 12 for the Randomized Immune-related Adverse Event (irAE) (ir-colitis or ir-hepatitis)Time frame: Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.